Mette Yde Dam

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

Kim Hørslev‐Petersen, Merete Lund Hetland, Peter Junker et al. · Annals of the Rheumatic Diseases · 2013 · 124 citations · Full text

The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats

Britt Elmedal, Mette Yde Dam, Michael J. Mulvany et al. · British Journal of Pharmacology · 2004 · 86 citations · Full text

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

S. B. Krintel, Christian Dehlendorff, Merete Lund Hetland et al. · The Pharmacogenomics Journal · 2015 · 67 citations

Inflammation, Rheumatology, Double-blind Placebo-controlled Study +11

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

Mette Axelsen, Iris Eshed, Kim Hørslev‐Petersen et al. · Annals of the Rheumatic Diseases · 2014 · 63 citations · Full text

Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry

Tanja Schjødt Jørgensen, Lars Erik Kristensen, Robin Christensen et al. · Lara D. Veeken · 2015 · 56 citations